AltPep Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 33

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $52.9M

  • Investors
  • 9

AltPep General Information

Description

Operator of a proprietary peptide-based platform intended to diagnose and neutralize toxic precursors to amyloid diseases. The company's platform provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic, and anti-biofilm applications that focus on soluble oligomer binding assay for early detection of toxic oligomers in Alzheimer's disease, enabling healthcare institutes to improve human health through the early detection and treatment of amyloid diseases.

Contact Information

Website
www.altpep.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 800
  • Seattle, WA 98109
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 800
  • Seattle, WA 98109
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AltPep Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 22-Jun-2023 $52.9M Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 12-Jan-2021 Completed Startup
3. Debt - General 27-Sep-2020 Completed Startup
2. Accelerator/Incubator 17-Apr-2019 Completed Startup
1. Accelerator/Incubator 08-Apr-2019 Completed Startup
To view AltPep’s complete valuation and funding history, request access »

AltPep Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Preferred
Series A-4
Series A-3
Series A-2 400,352 $0.000100 8% $1.25 $1.25 1x $1.25 1.1%
Series A-1 8,171,743 $0.000100 8% $2.53 $2.53 1x $2.53 22.45%
To view AltPep’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AltPep Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a proprietary peptide-based platform intended to diagnose and neutralize toxic precursors to amyloid disease
Drug Discovery
Seattle, WA
33 As of 2025

Framingham, MA
 

Naples, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AltPep Competitors (84)

One of AltPep’s 84 competitors is Alzheon, a Venture Capital-Backed company based in Framingham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alzheon Venture Capital-Backed Framingham, MA
Attralus Venture Capital-Backed Naples, FL
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Sirnaomics Formerly VC-backed Gaithersburg, MD
Prevail Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 84 competitors. Get the full list »

AltPep Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AltPep Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eli Lilly and Company Foundation Limited Partner Minority
Gentium Partners Accelerator/Incubator Minority
Partners Investment Venture Capital Minority
S32 Venture Capital Minority
Senator Investment Group Hedge Fund Minority
You’re viewing 5 of 9 investors. Get the full list »

AltPep FAQs

  • When was AltPep founded?

    AltPep was founded in 2018.

  • Where is AltPep headquartered?

    AltPep is headquartered in Seattle, WA.

  • What is the size of AltPep?

    AltPep has 33 total employees.

  • What industry is AltPep in?

    AltPep’s primary industry is Drug Discovery.

  • Is AltPep a private or public company?

    AltPep is a Private company.

  • What is the current valuation of AltPep?

    The current valuation of AltPep is .

  • What is AltPep’s current revenue?

    The current revenue for AltPep is .

  • How much funding has AltPep raised over time?

    AltPep has raised $76M.

  • Who are AltPep’s investors?

    Eli Lilly and Company Foundation, Gentium Partners, Partners Investment, S32, and Senator Investment Group are 5 of 9 investors who have invested in AltPep.

  • Who are AltPep’s competitors?

    Alzheon, Attralus, Vedanta Biosciences, Sirnaomics, and Prevail Therapeutics are some of the 84 competitors of AltPep.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process